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Abstract
Transposable elements (TEs) comprise a large fraction of mammalian genomes. A number of these elements are
actively jumping in our genomes today. As a consequence, these insertions provide a source of genetic variation
and, in rare cases, these events cause mutations that lead to disease. Yet, the extent to which these elements
impact their host genomes is not completely understood. This review will summarize our current understanding of
the mechanisms underlying transposon regulation and the contribution of TE insertions to genetic diversity in the
germline and in somatic cells. Finally, traditional methods and emerging technologies for identifying transposon
insertions will be considered.
Introduction
In the 60 years since Barbara McClintock first discov-
ered transposable elements (TEs), it has become increas-
ingly recognized that these mobile sequences are
important components of mammalian genomes and not
merely ‘junk DNA’. We now appreciate that these ele-
ments modify gene structure and alter gene expression.
Through their mobilization, transposons reshuffle
sequences, promote ectopic rearrangements and create
novel genes. In rare cases, TE insertions which cause
mutations and lead to diseases both in humans and in
mice have also been documented. However, we are at
the very earliest stages of understanding how mobile
element insertions influence specific phenotypes and to
the extent to which they contribute to genetic diversity
and human disease.
TEs are categorized into two major classes based on
their distinct mechanisms of transposition. DNA trans-
posons, referred to as Class II elements, mobilize by a
‘cut-and-paste’ mechanism in which the transposon is
excised from a donor site before inserting into a new
genomic location. These elements are relatively inactive
in mammals, although one notable exception is a piggy-
Bac element recently identified to be active in bats ([1],
R Mitra and N Craig, personal communication). In
humans, DNA transposons represent a small fraction
(3%) of the genome [2]. Retrotransposons, also known
as Class I elements, mobilize by a ‘copy-and-paste’
mechanism of transposition in which RNA intermedi-
ates are reverse transcribed and inserted into new geno-
mic locations. These include long terminal repeat (LTR)
elements such as endogenous retroviruses, and non-LTR
retrotransposons. Endogenous retroviruses are remnants
of viruses that have lost the ability to re-infect cells.
These elements, which comprise 8% of the human gen-
ome, perform reverse transcription in cytoplasmic virus-
like particles [2]. In contrast, non-LTR retrotransposons
undergo a distinct mechanism of transposition whereby
their RNA copies undergo reverse transcription and
integration through a coupled process that occurs on
target genomic DNA in the nucleus [3-5].
Of all mobile element families, only the retrotranspo-
sons remain actively mobile in the human and primate
genomes and serve as ongoing sources of genetic varia-
tion by generating new transposon insertions. LINEs
(long interspersed nucleotide elements) represent the
most abundant autonomous retrotransposons in
humans, accounting for approximately 18% of human
DNA. Non-autonomous elements such as SINEs (short
interspersed nucleotide elements) and SVAs [hybrid
SINE-R-VNTR (variable number of tandem repeat)-Alu
elements] require LINE-1 (L1) encoded proteins for
their mobilization [2,6-9]. Together, SINEs and SVA ele-
ments occupy ~13% of the human genome.
I ti sb o t hi m p r e s s i v ea n dp u z z l i n gt h a ta l m o s th a l fo f
our genome is composed of these repeat sequences.
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and harmful TE insertions events should be selected
against, while beneficial insertions should gain a selec-
tive advantage and thus be retained. Indeed, the most
successful transposons have co-evolved with their hosts.
Most transposable element insertions are expected to
have few consequences for the host genome and, there-
fore, have little to no impact on gene function [10].
Rarely, transposon insertions will have a deleterious
effect on their host genome, resulting in human disease.
To date, approximately 65 disease-causing TE insertions
(due to L1, SVA and Alus) have been documented in
humans [11]. Less frequently recognized are instances in
which transposons have made innovative contributions
to the human genome. In these cases, mobile element
sequences have been co-opted by the host genome for a
new purpose. For example, approximately 150 human
genes have been derived from mobile genetic sequences
[2,12,13]. Perhaps the best studied example of a domes-
ticated transposon is the RAG1 endonuclease, which
initiates V(D)J recombination leading to the combinator-
ial generation of antigen receptor genes. The RAG
endonucleases have been demonstrated to function as
transposases in vitro, providing strong support for the
idea that the V(D)J recombination machinery evolved
from transposable elements [14-16].
In this review, we examine mechanisms of transposon
regulation and discuss how TE insertions account for
genetic diversity in the germline and in somatic cells.
Traditional methods and recently developed techno-
logies for identifying these insertions will also be
considered.
Mechanisms of TE regulation
Expansion of mobile elements occurs when de novo
insertions are transmitted through the germline to sub-
sequent generations. Indeed, successful metazoan trans-
posons often show germline-restricted expression. As
TEs pose a significant threat to genome integrity,
uncontrolled activation of these elements would imperil
both the host and the element. It appears that, as a con-
sequence, metazoan genomes have evolved sophisticated
mechanisms to limit the mobilization of these elements.
DNA methylation is, perhaps, the most well under-
stood mechanism involved in the regulation of TEs in
the germline of plants, fungi and mammals [17-20].
Cytosine methylation silences LTR and non-LTR ele-
ments by blocking transcription of retrotransposon
RNA. Host suppression mechanisms appear to function
post-transcriptionally as well. For example, the prema-
ture termination of transcription and alternative splicing
inhibits expression of LINE-1 elements [21,22]. A family
of RNA/DNA editing enzymes with cytosine deaminase
activity known as APOBECs (apolipoprotein B mRNA
editing enzyme, catalytic polypeptide) has been found to
inhibit LINE-1, Alu, and mouse IAP (intracisternal A
particle) elements [23]. Interestingly, suppression of ret-
rotransposons by APOBECs does not require any editing
activity, suggesting that these proteins may carry out a
novel function in addition to their ability to act as cyto-
sine deaminases. Several groups have proposed that
APOBECs may sequester retrotransposon RNA in cyto-
plasmic complexes, although additional studies are war-
ranted in order to prove this hypothesis [24,25]. RNA
interference is believed to control retrotransposition
[26], although the observed effect in mammalian cells
in vitro is modest [27,28].
Recently, a novel form of mobile element control has
emerged that involves small RNAs in germ cells [29]. At
the heart of this pathway is a class of small RNAs [piwi-
interacting RNA (piRNAs)] that bind to the germline-
restricted Piwi subclass of the Argonaute family of RNA
interference effector proteins. In Drosophila, piRNAs are
enriched in sequences containing retrotransposons and
other repetitive elements. Disruption of Piwi proteins
results in the reduction in piRNA abundance and trans-
poson derepression [30,31]. A series of elegant studies
in Drosophila and zebrafish directly implicated Piwi pro-
teins in piRNA biogenesis to maintain transposon silen-
cing in the germline genome [32-34]. These findings
have led to the idea that piRNAs might immunize the
Drosophila germline against potentially sterilizing trans-
position events [32,35].
Mutations in two mouse Piwi orthologues (Mili and
Miwi2) result in the loss of TE methylation in the testes,
transposon derepression and meiotic arrest during sper-
matogenesis [36,37]. Interestingly, the mouse MAEL-
STROM (MAEL) protein was found to interact with
MILI and MIWI in the germline-specific structure
nuage [38], suggesting that MAEL may also function in
this pathway. Nuage (French for ‘cloud’) is a perinuclear
electron-dense structure found in the germ cells of
many species [39]. In flies, Mael is required for the
accumulation of repeat-associated small interfering
RNAs (siRNAs) and repression of TEs [40]. Soper et al.
demonstrated that loss of Mael leads to germ cell
degeneration (at the same point in meiosis as Mili and
Miwi2 mutants) and male sterility in mice [41]. In addi-
tion, they provided evidence that the mammalian MAEL
protein is essential for the silencing of retrotransposons
and determined that early meiosis is a critical timepoint
when transposon control is established in the male
germline. More recently, a similar role for another germ
cell protein, GASZ, has been uncovered [42]. Given that
MAEL, MILI, MIWI and GASZ all localize to nuage
(chromatoid body in mammals), this structure is likely
where the piRNA pathway defends the germline genome
from the invasion of unchecked transposable elements.
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New retrotransposon insertions arising in or passing
through the germline can lead to constitutional genetic
diseases in humans, although these are uncommonly
recognized events. Not surprisingly, it is the TE families
most actively propagating themselves in the human gen-
ome that are found to cause these diseases, namely and
in order of prevalence, Alus, L1 s and SVAs.
As a result of male hemizogosity for the X chromo-
some, loss-of-function mutations affecting boys have
been disproportionately described. Examples include
numerous Alu and L1-induced coagulopathies by dis-
ruption of coagulation factor VIII or factor IX [43,44],
Alu and SVA insertions causing immunodeficiency by
disrupting BTK [45] and LINE-1 insertions in the large
dystrophin locus resulting in muscular dystrophies and
cardiomyopathies [46-48].
Autosomal transposon insertions leading to human
disease have also been described. These tend to pheno-
copy otherwise autosomal dominant diseases caused by
mutation of the transposon target locus. Examples
include an intronic Alu insertion disrupting function of
the NF1 tumour suppressor and causing clinical neurofi-
bromatosis [49] and a small number of independent Alu
insertions affecting fibroblast growth factor receptor 2
(FGFR2) and causing malformations with craniosynosto-
sis categorized as Apert syndrome [50,51].
Thus, while most de novo insertions are likely to be
passed on as phenotypically silent repeats, it is well
established that transposon insertions are relevant to
human clinical genetics and can have severe phenotypic
consequences in rare cases [52,53]. There remains sig-
nificant speculation about whether our understanding of
this is limited by the technical difficulties in detecting
these sequences (discussed below) or if retrotransposi-
tion is indeed effectively prevented so that de novo
insertions uncommonly underlie human disease.
Transposon insertions in somatic cells
There is a widely accepted belief that truly ‘selfish’
genetic elements must mobilize selectively in the germ-
line or during early development in order to guarantee
their evolutionary success. However, recent evidence
from several laboratories challenges this notion. Belancio
and colleagues reported that both full-length and pro-
cessed L1 transcripts are detected in human somatic tis-
sues as well as in transformed cells [54]. Kubo and
colleagues demonstrated that L1 retrotransposition
occurs in a low percentage of primary fibroblasts and
hepatocyes when an adenoviral delivery system is
employed to express the L1 element [55]. Additionally,
L1 somatic retrotransposition events have been discov-
ered in blastocysts from transgenic mouse and rat
models expressing a human L1 element [56]. These data
suggest that L1 elements contribute to somatic mosai-
cism. The proposed model is that L1 RNA transcribed
in germ cells is carried over through fertilization and
then integrates during embryogenesis. At least one case
of human disease appears traceable to a similarly timed
insertion in a mosaic mother who transmitted the inser-
tion to her child [57]. Somatic insertions have also been
identified in mouse models expressing a synthetic
mouse L1 element [58]. However, in these studies the
elements are expressed from heterologous promoters.
Gage and colleagues reported that L1 retrotransposi-
tion occurs in cultured mouse neuronal progenitor cells
and in a mouse model harboring a human L1 element
[59]. Based on these findings, it is hypothesized that L1
retrotransposition events might contribute to neuronal
plasticity and, perhaps, individuality. In a recent follow-
up study, Gage and colleagues detected an increase in
the copy number of endogenous L1 in several regions of
the adult human brain compared to the copy number of
these elements in liver or heart genomic DNA from the
same person [60]. In some cases, the brain samples con-
tained ~80 additional copies of L1 sequence per cell.
The functional consequences of these findings are, as
yet, unknown and many questions remain regarding
whether these brain-specific L1 insertions could poten-
tially affect neuronal cell function. Despite these unan-
swered questions, interesting parallels can be drawn
between neuronal cell diversity and the immune system.
Namely, immune cells are the only other somatic cell
type known to undergo an orchestrated genomic
sequence-level alteration process whereby genes that
encode antibodies are shuffled to create a host of anti-
bodies that recognize a large number of antigens. Given
that the human nervous system embodies a seemingly
equally astounding degree of complexity and variability,
it is possible that L1 mobilization may play a role in
somatic cell diversity. Yet, dysregulation of transposon
control mechanisms in the brain might also contribute
to neurologic disease.
The extent to which TE insertions may generate diver-
sity in somatic cells remains largely unexplored. It
remains unclear why transposons do not hop more
often in somatic cells. One possibility is that a transpo-
son defense pathway present in somatic cells has yet to
be discovered. One potential candidate involved in
somatic TE repression might be the P body (processing
body), the somatic equivalent of the germline-specific
structure nuage. These cytoplasmic structures contain
enzymes involved in RNA turnover, including members
of the RNA-induced silencing complex. L1 RNA and
ORF1 have been shown to accumulate in stress gran-
ules, which associate with P bodies in somatic cells [61].
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how coordinate repression of TEs in somatic cells,
although additional studies are necessary.
Mobile elements and cancer
A hallmark of neoplastic proliferation is the accumula-
tion of somatic genetic changes. Many types of cancer
involve recurrent karyotypic abnormalities or other
forms of genomic instability. The roles that mobile ele-
ments may play in these processes have been largely
speculative. In humans, constitutionally integrated
transposons have fairly well established roles as sub-
strates in non-allelic homologous recombinations; but
do they also potentiate oncogenesis by somatic expres-
sion of, for example, genotoxic L1-encoded proteins?
Beyond this, are they capable of completing retrotran-
sposition in such a way as to inactivate key tumor sup-
pressor genes? In rare cases, they do appear to do the
latter. For example, LINE-1 retransposition was shown
to be an important step in the development of a colon
cancer when a tumor-specific exonic insertion in ade-
nomatosis polyposis coli (APC)w a sd e s c r i b e d[ 6 2 ] .
Using an approach that combines linker-mediated
polymerase chain reaction (PCR) and high-throughput
sequencing (to be discussed in the next section), Iskow
and colleagues recently identified several L1 insertions
in human lung tumor samples [63]. Although muta-
tions with functional consequences were not demon-
strated, these data support a model whereby L1
activity creates tumor genomic heterogeneity. This
underscores at least possible roles for transposon
insertions in tumor progression.
Suggesting that transposons may have tumor-specific
effects dependent on their expression is the observation
that demethylation of their promoter sequences have
been described in several human tumors. Several
examples for the L1 promoter are described in Table 1.
In most cases, studies have not convincingly carried
these observations further to document that this results
in full-length LINE-1 transcripts or expression of func-
tional ORF1p and ORF2p proteins. In a few documented
cases, full length L1 RNA in cancer cell lines [54,64] and
expression of ORF1p in pediatric germ cell tumors [65]
and breast cancer [66] have been shown. Thus, it is pos-
sible that tumors provide an environment where trans-
position events can occur and be selected for in
transformation. In at least one animal model, the mouse
Dnmt1 hypomorph, activation of endogenous retroele-
ments is involved in lymphomagenesis. Presumably,
hypomethylation caused by compromise of the DNA
methyltransferase leads to unchecked activity of endo-
genous IAPs which then integrate in the Notch1 locus
to generate an oncogenic gain-of-function allele [67].
This occurred independently but recurrently in seven of
the 16 lymphomas studied.
While the genotoxic potential of L1 encoded ORF2p
has been recognized, a recent paper by Lin et al.[ 6 8 ]
raised an interesting model suggesting that the protein
contributes to tumor development by inducing double-
stranded DNA (dsDNA) breaks at specifically targeted
sites to which it is recruited. Using chromatin immuno-
precipitation in prostate adenocarcinoma cells, the
authors demonstrated an androgen ligand-dependent
localization of ORF2p to a prostate cancer chromosomal
translocation interval. Rather than promoting retrotran-
sposition, their model suggests the endonuclease activity
leaves DNA breaks thus subjecting the region to erro-
neous repair by non-homologous end joining pathways
ultimately responsible for the translocation. What fac-
tors are responsible for the recruitment and whether
ORF2p functions similarly at other breakpoint hot spots
in other neoplasias remains unknown.
Table 1 Studies describing long interspersed nucleotide element (LINE)-1 hypomethylation in malignant tissues
Tumor Evidence for LINE hypomethylation Reference
Breast cancer 5’ flanking sequences of hypomethylated L1 homo sapien elements were isolated from T-47 D cells by
inverse polymerase chain reaction (PCR)
[94]
Chronic myeloid leukaemia
(blast phase)
Methylation-specific PCR of primary samples; hypomethylation associated with blast crisis, high levels of
BCR-ABL messenger RNA, resistance to tyrosine kinase inhibitor chemotherapy
[95]
Chronic lymphocytic
leukaemia
A variety of primary specimens analysed by HpaII restriction enzyme digest and Southern blot analysis [96]
Colorectal adenocarcinoma As compared to neighbouring normal colon;
colorectal carcinomas with sporadic microsatellite instability a noted exception; alternative progression
pathways proposed
[96-98]
Hepatocellular carcinoma Hepatocellular carcinomas compared to surrounding cirrhotic liver; HpaII restriction enzyme digest [99]
Neuroendocrine tumours Well-differentiated pancreatic endocrine and carcinoid tumours compared to surrounding tissue; LINE
hypomethylation correlates with lymph node metastasis and cytogenetic aberrations
[100]
Prostate cancer Adenocarcinoma compared to surrounding tissue; hypomethylation of L1 s associated with preoperative
PSA, Gleason grade, and clinical stage; associated independently with cytogenetic abnormalities
[101-103]
Urothelial carcinoma L1 hypomethylation detected by Southern blot in most specimens [104-106]
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cancer, it should be noted that several laboratories have
utilized transposons as tools for cancer gene identifica-
tion in forward genetic insertional mutagenesis screens
in mice. For example, the Sleeping Beauty (SB) DNA
transposon system has been successfully used to identify
novel cancer genes in tissues that could not be pre-
viously analysed by slow transforming retroviruses
[69,70]. Recently, this approach has been modified
through the conditional activation of the SB in specific
tissues [71,72]. With the recent development of a
codon-optimized L1 element, it appears that retrotran-
sposons may also serve as useful mutagenesis tools
[58,73]. As these elements mobilize by a copy and paste
mechanism of retrotransposition, their donor elements
are stable. L1 mouse models may also be controlled by
tissue-specific promoters and be engineered to contain
gene traps [74]. One potential advantage of an unbiased
TE-based approach is the ability to study how specific
mutations affect tumor cell initiation, progression and
maintenance in well-defined, genetically engineered
mouse models. Thus, it is likely that these models will
provide a complementary approach to cancer genome
sequencing studies by uncovering functionally relevant
mutations that can further be studied as potential thera-
peutic targets.
Strategies for identifying TE insertions
The majority of human genomic transposon sequences
are inactive due to the accumulation of mutations and
rearrangements that has occurred during evolution, as
well as 5’ truncations during their insertion that render
L1 copies inactive. In the case of the former, these older
elements are essentially ‘fixed’ in human populations
today. With all this genomic clutter, identifying poly-
morphic elements and de novo somatic insertions
requires directed strategies in order to identify younger,
potentially active, transposon copies. Methods for identi-
fying this complement of novel TE insertions have been
described and are under rapid development as genomic
methodologies continue to avail themselves (Figure 1).
First generation methods for recovery of novel TEs
Many of the first assays for mobile elements were PCR-
b a s e da n dr e l i a n to ng e l - b a s ed amplicon separation to
distinguish the presence or absence of a particular ele-
ment. Examples include a subtractive suppression PCR
assay termed amplification typing of L1 active subfami-
lies (ATLAS) [75], a random decamer PCR called L1
display [76] and a ligation-mediated PCR called L1
insertion dimorphisms identification by PCR (LIDSIP)
[77]. These techniques exploited sequences specific to
young L1 families and gave investigators the first
insights into the impressive degree of L1 polymorphism
in humans. However, they did not lend themselves read-
ily to comprehensive L1 mapping in large numbers of
samples.
Mining genomic sequencing data for TE insertions
Analyses of genomic sequencing data have since con-
tributed significantly to our understanding of poly-
morphic retroelements in humans, which will
presumably accelerate with the ongoing exponential
increases in available data. In silico mining of the
human genome draft [78,79], the Venter genome [80]
and comparative sequence analysis of the human and
chimpanzee genomes have been performed in order to
detect species-specific transposon insertions [81-83].
These studies have revealed that subfamilies of Alu,
LINE-1 and SVA elements have differentially amplified
in humans and chimpanzees. Building on the foundation
of the human reference genome, relatively new con-
certed efforts are underway which may harness sequen-
cing methods to provide insights into structural
variation. Paired-end mapping of size selected DNA
fragments represents a large-scale approach to identify
sizable variants in the genome. For example, using this
method with fragments cloned into fosmids, it is possi-
ble to detect large insertions and deletions (indels)
embedded in repetitive DNA [84,85]. Beck and collea-
gues recently showed this is a powerful means of iden-
tify young, polymorphic full-length L1 s, which are high
in retrotransposition activity [86]. Moreover, this
method appears to effectively identify the source of par-
ent elements responsible for ongoing L1 insertions in
human populations today.
High throughput TE mapping methods
Technologic developments in sequencing methods and
microarray platforms are expanding methods for high
throughput TE discovery in the post-genomic era. Several
laboratories recently published targeted methods for
recovering TE insertion sites that, in combination with
high resolution microarrays or deep sequencing, allow
researchers to catalogue novel transposition events on a
genome-wide basis [63,87-89]. For example, with the
Boeke laboratory, we approached L1(Ta) mapping in the
human genome using a ligation mediated PCR method
known as vectorette PCR [88]. In this method, non-com-
plementary oligonucleotides are ligated to DNA ends and
serve to bind a PCR primer only after first strand synth-
esis is initiated from the L1(Ta). The result is an amplifi-
cation of unique genomic DNA adjacent to the mobile
element. Individual insertion sites can be recognized in
this complex mixture of amplicons by labelling and
hybridizing to genomic tiling microarrays or by deep
sequencing. These data suggest that the rate of new L1
insertions in humans is nearly double previous estimates,
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births, a finding that agrees well with data recently
described by Kazazian and colleagues [87]. These types of
approaches will undoubtedly be useful in detecting novel
TE insertions in both normal individuals and in patients
affected with genetic diseases in the future.
TEs and human genetic variation
To what extent do mobile elements contribute to
human genetic diversity? This is a complex question,
which is just beginning to be explored in greater depth.
Sequencing of the human genome revealed that indivi-
dual genomes typically exhibit 0.1% variation [2]. Most
of the individual genome variation can be attributed to
single nucleotide polymorphisms (SNPs), chromosome
rearrangements, copy number variants and repetitive
elements. The Human Genome Project revealed that
there are 2000 polymorphic L1 elements and 7000 poly-
morphic Alus in humans, although it is postulated that
the actual number is significantly higher due to ongoing
transposition and individual TE polymorphisms. In an
effort to detect the degree of genetic variation that is
caused by transposable elements, Bennett and colleagues
[90] analysed DNA re-sequencing data from 36 people
of diverse ancestry. Indel polymorphisms were screened
in order to find those that were caused by de novo
transposon insertions. They estimated that human
populations harbour an average estimated 2000 common
transposon insertion polymorphisms. In general, these
results are consistent with several other studies regard-
ing Alu element polymorphisms [8] and L1-Hs insertion
polymorphisms [75,76,78,91,92].
In an attempt to identify the number of active poly-
morphic L1 elements in the human genome, Brouha
Figure 1 Techniques for identifying transposon insertions. (A) Polymerase chain reaction (PCR)-based assays detect transposable element
(TE) insertions. L1 display utilizes primers specific to particular subfamilies of LINE-1 elements. Using this method, candidate dimorphic L1
insertions have been identified. The ATLAS technique employs the principles of L1 display and suppression PCR. Genomic DNA is digested and
ligated to oligonucleotide primers, and used as a template in a PCR reaction containing L1 and linker-specific primers. Primary PCR products are
then used as templates in a linear PCR reaction containing a radiolabelled subfamily-specific L1 primer. Radiolabelled products are detected by
electrophoresis and autoradiography. (B) A comparative genomics approach to identify TE insertions and deletions is depicted. For example, the
completion of the draft chimpanzee genome sequence provided an opportunity to identify recently mobilized transposons in humans and
chimpanzees. If a transposon insertion is present in only one of the two genomes, it is inferred that the insertion occurred since the existence of
their most common recent ancestor (~6 million years ago). (C) A paired-end mapping approach is shown. This method entails generating
paired-ends of several kilobase fragments, which are sequenced using next generation sequencing methodologies. Differences between the
paired-end reads and a reference genomic region reveal the presence of structural variation. Simple insertions and deletions can be detected
using this method. (D) A next generation sequencing method is shown. Selective amplification of the 3’ end of a transposon is performed
followed by deep sequencing. This short-read sequencing approach is able to detect precise insertion positions. (E) Microrray-based methods
involve the hybridization of ligation-mediated PCR products to genomic tiling arrays. Specifically, vectorettes are ligated to restriction enzyme-
digested genomic DNA. The amplified fragments include the 3’ end of a transposon sequence and unique flanking genomic DNA. These
amplicons are hybridized to genomic tiling microarrays.
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elements from an early draft of the human genome
sequence. Of these, they determined that 38 (44%) are
polymorphic for presence in the human genome. In
addition, a similar number of elements were identified
to be active in a cell-culture based retrotransposition
assay. Based on these results, it is estimated that there
are 80-100 active L1 s in the average diploid genome.
Of these, in vitro retrotransposition assays suggest only
a small number are highly active and have accounted
for the majority of de novo insertions [91].
Recently, several groups have focused their efforts on
determining what fraction of structural variants (SVs) in
the human genome is due to TE sequences. Korbel and
colleagues [84] employed a paired-end mapping techni-
que to identify ~1000 SVs and reported that the number
of these variants in humans is significantly higher that
originally appreciated. Xing et al. [80] analysed ~8000
SVs with the goal of identifying those that are associated
with mobile elements. Computational analyses and
experimental validation revealed that roughly 700 novel
transposable element insertion events due to Alus,L 1
elements and SVAs are found in an individual diploid
genome. Transposon-mediated deletions were also
detected. The Jorde laborato r yr e c e n t l yd e m o n s t r a t e d
that the presence of a fixed Alu insertion is predictive of
an elevated local recombination rate, which may further
contribute to non-allelic recombination events [93].
Indeed, it has become increasingly apparent that TEs
play an important role in the generation of structural
variants between individuals and this is an exciting area
ripe for further study. Future efforts focused on charac-
terizing the full extent of mobile element associated
structural variants and probing their potential functional
consequences are warranted.
Conclusions
Our understanding of the basic biology of TEs has
expanded dramatically in the 60 years since their initial
discovery. Yet, there are still many open questions
awaiting further study. For example, the mechanisms of
transposon regulation and mobilization in the germline
and somatic cells have not been fully elucidated. If we
appreciate where, when and how these processes occur,
we will ultimately better understand the impact of these
elements on host genomes and the extent to which they
contribute to diversity.
Although major advances have been made in the iden-
tification of transposon insertions in humans, we are at
the very earliest stages of recognizing the full implica-
tions of these findings. It is clear that TE insertions pro-
vide a rich source of inter-individual genetic variation.
With the continued optimization of technologies that
are able to identify all transposon insertions, we will
undoubtedly gain a better understanding of the extent
of TE diversity in individual genomes, in human popula-
tions and in disease states.
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